Stereotactic Body Radiotherapy Versus Metastasectomy in Patients With Pulmonary Metastases From Soft Tissue Sarcoma

The lung is the preferred site of metastasis from soft tissue sarcoma (STS). This systematic review aims to evaluate the outcomes of stereotactic body radiotherapy (SBRT) and metastasectomy (MTS) for the treatment of lung metastases from STS. A systematic review was carried out according to the PRIS...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical oncology (Royal College of Radiologists (Great Britain)) Ročník 32; číslo 5; s. 303 - 315
Hlavní autori: Tetta, C., Londero, F., Micali, L.R., Parise, G., Algargoush, A.T., Algargoosh, M., Albisinni, U., Maessen, J.G., Gelsomino, S.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Elsevier Ltd 01.05.2020
Predmet:
Humans
Lung metastasis
Lung Neoplasms - mortality
Lung Neoplasms - secondary
Lung Neoplasms - surgery
metastasectomy
Metastasectomy - mortality
Radiosurgery - mortality
sarcoma
Sarcoma - mortality
Sarcoma - pathology
Sarcoma - surgery
soft tissue sarcoma
stereotactic body radiotherapy
Survival Rate
Treatment Outcome
stereotactic body radiotherapy
sarcoma
Lung metastasis
soft tissue sarcoma
metastasectomy
ISSN:0936-6555, 1433-2981, 1433-2981
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The lung is the preferred site of metastasis from soft tissue sarcoma (STS). This systematic review aims to evaluate the outcomes of stereotactic body radiotherapy (SBRT) and metastasectomy (MTS) for the treatment of lung metastases from STS. A systematic review was carried out according to the PRISMA protocol. PubMed, Medline, EMBASE, Cochrane Library, Ovid and Web of Knowledge databases were searched for English-language articles to December 2018 using a predefined strategy. Retrieved studies were independently screened and rated for relevance. Data were extracted by two researchers. In total, there were 1306 patients with STS: 1104 underwent MTS and 202 had SBRT. The mean age ranged from 40 to 55.8 years in the MTS group and from 47.9 to 64 years in the SBRT group. The cumulative death rate was 72% (95% confidence interval 59–85%) in the MTS group and 56% (38–74%) in the SBRT group. The cumulative mean overall survival time was 46.7 months (36.4–57.0%) in the MTS group and 47.6 months (33.7–61.5%) in the SBRT group. The cumulative rate of patients alive with disease was 5% (2–9%) in the MTS group and 15% (6–36%) in the SBRT group. Finally, the cumulative rate of patients alive without disease in the two groups was 19% (9–29%) and 20% (10–50%), respectively. Our study showed that local treatment of pulmonary metastases from STS with SBRT, compared with surgery, was associated with a lower cumulative overall death rate and similar overall survival time and survival rates without disease. By contrast, SBRT was associated with a higher survival rate with disease than MTS. Large randomised trials are necessary to confirm these findings and to establish whether SBRT may be a reliable option for early stage disease.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0936-6555
1433-2981
1433-2981
DOI:10.1016/j.clon.2020.01.005